Autoimmune Hemolytic Anemia: Initial Management

Autoimmune hemolytic anemia (AIHA) occurs when the immune system mistakenly attacks red blood cells. The goal of initial management is to quickly suppress the immune system and reduce red blood cell destruction.

First-Line Therapy Rationale

The primary goal is rapid immunosuppression. Corticosteroids are the cornerstone of initial therapy for AIHA because they effectively reduce antibody production and hemolysis.

• Prednisolone: This corticosteroid is the standard first-line treatment. It helps decrease the immune system's attack on red blood cells, alleviating the anemia.

Evaluating Other Options

The other options are typically considered in specific circumstances or after initial therapy fails:

• Rituximab: Often used as a second-line treatment for patients who don't respond adequately to corticosteroids or for those needing long-term therapy.
• Emergency splenectomy: This surgical option is reserved for patients with severe AIHA who are refractory to medical management (corticosteroids and sometimes Rituximab). It is not an initial step.
• Plasmapheresis: This procedure removes antibodies from the blood. It may be used in very severe or specific situations (e.g., certain types of AIHA like cold agglutinin disease crisis) but is not the standard initial treatment for most AIHA cases.

Therefore, the initial step in managing severe autoimmune hemolytic anemia involves starting corticosteroids like Prednisolone.